Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003

Trial Profile

Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Adverse reactions
  • Sponsors CSL Behring
  • Most Recent Events

    • 20 Jun 2019 According to a CSL Behring media release, the company is committed to further analysis based on the trial extension results to continue to advance patient care and deliver innovation that will improve quality of life for people living with CIDP.
    • 20 Jun 2019 According to a CSL Behring media release, new insights from the PATH trial extension including long-term Quality of Life (QoL) and outcomes data analyses, and evaluation of IgG levels as a potential biomarker to predict treatment response in the treatment of CIDP will be presented at the 2019 Peripheral Nerve Society Annual Meeting (22nd-26th June 2019, in Genoa, Italy).
    • 17 Jul 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top